Role of Molecular Targeted Therapeutic Drugs in Treatment of Oral Squamous Cell Carcinoma: Development and Current Strategies-A Review Article

被引：3
作者：
Singh, Himanshu [1 ]
Patel, Vedant [2 ]
机构：
[1] Index Inst Dent Sci, Dept Oral & Maxillofacial Pathol & Oral Microbiol, Indore 452016, Madhya Pradesh, India
[2] Index Inst Dent Sci, Dept Prosthodont & Crown & Bridge, Indore, Madhya Pradesh, India
来源：
GLOBAL MEDICAL GENETICS | 2022年 / 09卷 / 03期
关键词：
oral squamous cell carcinoma; therapeutic drugs; targeted therapy; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; PHASE-II; CANCER; HEAD; SORAFENIB; CETUXIMAB; EXPRESSION; CHEMORADIATION; COMBINATION;
D O I：
10.1055/s-0042-1756663
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Because of active advancement in the field of biomedicine, people have in-depth knowledge of biological nature of malignant tumors and are able to recognized the overexpression of different molecules such as vascular endothelial growth factor receptor, cyclin-dependent kinase, and programmed cell death receptor. Presently, various targeted therapeutic drugs are used in different clinical trials in those patients suffering from oral squamous cell carcinoma. In this review, we converse about the various targeted therapeutic drugs and their advancement in the treatment of oral squamous cell carcinoma. This review scrutinizes the existing documentation in the literature related to the targeted therapies for oral squamous cell carcinoma. English language articles were searched in various databases such as PubMed, Scopus, Science Direct, and Google Scholar. The keywords used for searching are "oral squamous cell carcinoma," "targeted therapy," and "therapeutic drugs."
引用
收藏
页码：242 / 246
页数：5
相关论文
共 62 条
[1]  
Aldoss Ibrahim T, 2009, J Egypt Natl Canc Inst, V21, P157
[2]  
Banu S., 2020, Research Journal of Pharmacy and Technology, V13, P6243, DOI [10.5958/0974-360X.2020.01088.4, DOI 10.5958/0974-360X.2020.01088.4]
[3]   A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma [J].
Bauman, Julie E. ;
Arias-Pulido, Hugo ;
Lee, Sang-Joon ;
Fekrazad, M. Houman ;
Ozawa, Hiroyuki ;
Fertig, Elana ;
Howard, Jason ;
Bishop, Justin ;
Wang, Hao ;
Olson, Garth T. ;
Spafford, Michael J. ;
Jones, Dennie V. ;
Chung, Christine H. .
ORAL ONCOLOGY, 2013, 49 (05) :461-467
[4]   Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model [J].
Bozec, A. ;
Sudaka, A. ;
Toussan, N. ;
Fischel, J.-L. ;
Etienne-Grimaldi, M.-C. ;
Milano, G. .
ANNALS OF ONCOLOGY, 2009, 20 (10) :1703-1707
[5]   The role of cetuximab in the treatment of squamous cell cancer of the head and neck [J].
Burtness, B .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (08) :1085-1093
[6]   Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): Overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1 [J].
Chang, JT ;
Wang, HM ;
Chang, KW ;
Chen, WH ;
Wen, MC ;
Hsu, YM ;
Yung, BYM ;
Chen, IH ;
Liao, CT ;
Hsieh, LL ;
Cheng, AJ .
INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (06) :942-949
[7]   Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity [J].
Chen, LP .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (05) :336-347
[8]   The clinical significance of CDK1 expression in oral squamous cell carcinoma [J].
Chen, Xin ;
Zhang, Feng-He ;
Chen, Qiao-Er ;
Wang, Yuan-Yin ;
Wang, Yin-Long ;
He, Jia-Cai ;
Zhou, Jian .
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2015, 20 (01) :E7-E12
[9]   An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers [J].
Chohan, Tahir Ali ;
Qayyum, Aisha ;
Rehman, Kanwal ;
Tariq, Muhammad ;
Akash, Muhammad Sajid Hamid .
BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 :1326-1341
[10]   ALK1 as an emerging target for antiangiogenic therapy of cancer [J].
Cunha, Sara I. ;
Pietras, Kristian .
BLOOD, 2011, 117 (26) :6999-7006
1234567